A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer
Interventions: DRUG: Paclitaxel + bevacizumab therapy|DRUG: Paclitaxel + bevacizumab + atezolizumab
Sponsor: Japanese Foundation for Cancer Research
Collaborators: Chugai Pharmaceutical